frequency of individual chronic conditions, along with the incidence of comorbid 84 conditions, rises with age. Comorbidity is associated with polymedication and 85 increased risk of drug interactions. Many prognostic indices for the elderly incor-86 porating comorbidity are available [6] [7] [8] , but these scores are often complicated.
87
Disability. Disability is an important notion in geriatric assessment, and can 88 include both physical and mental impairments. It is defined as the difficulty or 89 dependency in carrying out activities essential to independent living, including both 90 essential personal care and household tasks, and activities that are important to 91 maintain a person's quality of life [9] . Disability, independent of its causes, is 92 associated with a higher risk of mortality; disabled adults are more likely to become 93 hospitalized [10] . In patients with MM, disability can be caused by orthopaedic 94 problems and pain; otherwise, the main causes of physical disability in the elderly 95 are chronic diseases such as cardiovascular disease, stroke or arthritis [10] . 
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96
Scoring system. It should therefore be mandatory to perform a geriatric assess-97 ment to all elderly patients with MM, at least over the age of 70, and/or suffering 98 from any kind of frailty, comorbidities or disability. One might consider that these 99 patients should be seen and assessed by geriatricians which expertise is indis-100 putable, but unfortunately this ideal assessment is rarely feasible due to the lack of 101 geriatricians and the increased number of elderly MM patients.
102
Very recently, a frailty score that combines age, comorbidities and functional 103 status (disability) has been proposed for elderly patients with MM [11] (n = 1,239), and >75 years (n = 651), and incidence and clinical impact of three 133 chromosomal aberrations [del(13), t(4;14), or del(17p)] were analyzed. Interest-134 ingly, they found a lower incidence of t(4; 14) and del(13) in the oldest patients,
135
whereas incidence of del (17p) in the MPT arm [22, 24, 25] , and this regimen is likely to be dethroned by less-toxic 211 associations.
212
The combination of cyclophosphamide, thalidomide and dexamethasone
213
(CTD) also improved response rates compared with MP. Evidence from the
214
Myeloma IX trial suggested a survival benefit in CTD-treated patients with 215 favourable cytogenetics, although early deaths from infections related to high-dose 216 dexamethasone were significant [26, 27] . 
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• SAR650984 is another anti-CD38 antibody whose association with lenalido- 
